Green R, Allen LH, Bjrke-Monsen AL, et al
Here's the honest picture: Strong: Consistent positive results in animal studies Multiple mechanisms that make biological sense Good safety profile in research settings Decades of study without major red flags Weak: Limited human clinical trials Not FDA approved for any indication Long-term effects unknown Quality control issues with commercial products The peptide is stuck in an odd place
What is not on the FDA's approved list: BPC-157, TB-500, CJC-1295, Ipamorelin, AOD-9604, Thymosin Alpha-1 (in the U.S.), and the other compounds under July review
The deconvoluted spectrum is reported on the Certificate of Analysis alongside the HPLC data, so the 16-residue chain and the N-terminal tyrosine substitution can both be confirmed against expected values before reconstitution
We have the experience, knowledge and tools to deliver real, effective results